This aggressive phase of the disease is referred to as castrate-resistant prostate cancer (CRPC) [5], which often maintains functional androgen receptor (AR) signaling that promotes PC by developing adaptive mechanisms including AR amplification, AR mutations, and expression of various AR splice variants [6,7]. This evidence concerns the gene AR and pachyonychia congenita.